How This Manufacturer Turned Big Pharma’s Commercialization Model Upside Down
When Pfizer acquired Biohaven for $11.6 billion, many big Pharma executives began to question their own beliefs and commercial tactics.
When Pfizer acquired Biohaven for $11.6 billion, many big Pharma executives began to question their own beliefs and commercial tactics.